Jaguar Health issues 481,584 shares to Streeterville to cut note balance
The debt-for-equity swap reduced the outstanding balance of a 2021 secured note by $3.4 million, filings show.
SEC filing (2)
Latest
8 stories
Monday, September 28
Thursday, September 24
Jaguar Health confirms 2025 note fully retired, updates outstanding share count to 1,463,958
A second 8-K from Jaguar Health confirms the 2025 Streeterville note was fully paid and cancelled and reports 1,463,958 shares outstanding as of September 24, 2026.
SEC filing (2)
Tuesday, September 15
Jaguar Health to complete 1-for-15 reverse stock split on September 17, 2026
The gastrointestinal drug developer said the split is meant to help it meet Nasdaq listing requirements, with split-adjusted trading starting Thursday.
SEC filing
Jaguar Health exchanges debt and preferred stock for common stock, closes Napo Therapeutics deal
Filing covers a note exchange with Lincoln Alternative Strategies, three preferred stock exchanges with Streeterville Capital, and completion of a stock purchase to acquire remaining Napo Therapeutics shares.
SEC filing
Thursday, September 3
Jaguar Health cuts ATM offering size after triggering Form S-3 share-value limit
Jaguar Health filed a September 3, 2026 supplement showing its at-the-market program reduced to about $4.78 million after hitting a threshold under General Instruction I.B.6 of Form S-3.
SEC filing
Wednesday, August 19
Jaguar Health reports Q2 2026 results, targets MVID NDA submission in Q2 2027
Jaguar said data on crofelemer in pediatric intestinal failure support an NDA package by year-end 2026, with submission planned for the second quarter of 2027.
SEC filing
Wednesday, July 15
Jaguar Health files two S-1s to register up to 46.3 million resale shares
The filings, both tied to June 9, 2026 financing deals, cover an equity line of credit and a preferred stock arrangement against just 4.9 million shares outstanding.
SEC filing (2)
Tuesday, July 14
Jaguar Health's Napo signs new crofelemer supply deal with Alivus after 2020 pact expired
The new agreement, dated July 9, 2026, runs through March 31, 2029 and replaces the prior manufacturing deal that lapsed on March 31, 2026.
SEC filing